Aeolus Provides Investor Update on Passage of Pandemic All-Hazards Preparedness Act of 2013
March 14, 2013 08:31 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Mar 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Bill Signed into Law by President Obama
Passed Senate...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2013 Financial Results
February 19, 2013 18:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Beginning Third Year of $118.4 Million BARDA Advance Research and...
Aeolus Pharmaceuticals Announces $3.2 Million Private Placement Financing
February 19, 2013 17:46 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Fiscal Year 2012 Results
January 02, 2013 10:59 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 2, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus' AEOL 10150 Supresses Overexpression of 31 Hypoxia-Related Genes Caused by Radiation Exposure
October 17, 2012 08:55 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 17, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
AEOL 10150 improves tissue oxygenation and reduces hypoxia-associated...
Aeolus Pharmaceuticals Provides Positive Update on FDA Meeting
September 06, 2012 08:05 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Sep 6, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2012 Financial Results
August 14, 2012 17:02 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Aug 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$1.4 million in revenue for third quarter 2012; $5.9...
Aeolus Pharmaceuticals Announces AEOL 10150 Diminishes Oxidative Stress and Nerve Damage Following Exposure to Nerve Agent
July 30, 2012 08:48 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jul 30, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
PositiveID Corporation Adds Chief Technology Advisor and Biodefense Expert as It Prepares for $3.1 Billion BioWatch Procurement
July 25, 2012 08:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., July 25, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of sophisticated airborne bio-threat...
Battelle Wins $102M NIAID Biodefense Research Contract
July 18, 2012 10:30 ET
|
Battelle
COLUMBUS, OH--(Marketwire - Jul 18, 2012) - Battelle has won a single-source award from the U.S. Department of Health and Human Services' National Institutes of Health for evaluation and testing...